Clinical Trials with Glycoprotein IIb/IIIa Receptor Antagonists in Acute Coronary Syndromes

• References

• 1 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-250
• 2 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1192; 326: 310-318
• 3 DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural mocardial infarction. N Engl J Med 1980; 303: 897-902
• 4 DeWood MA, Stifter WF, Simpson CA, Spores J, Eugster GS, Judge TP, Hinnen ML. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986; 315: 417-423
• 5 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
• 6 Collins R, Mac Mahons, Flather M. et al Clincal effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Br Med 1996; 313: 652-659
• 7 Ridker PM, Hebert PR, Fuster V, Henneken CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?. Lancet 1993; 341: 1574-1577
• 8 RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-830
• 9 Holdright D. et al Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994; 24: 39-45
• 10 Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after discontinuation of heparin. N Engl J Med 1992; 327: 141-145
• 11 Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294
• 12 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559
• 13 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
• 14 Agruirre FV, Topol E, Furguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM. Bleeding complications with the chimeric antibody to platelet GPIIb/IIIa Integrin in patients undergoing perculaneous coronary intervention. Circulation 1995; 91: 2882-2890
• 15 Topol EF, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M. et al Randomised trial of coronary intervention with antibody against platelet lib/ Ilia integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994; 343: 881-886
• 16 Van de Werf. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. Eur Heart J 1996; 17: 325-326
• 17 Tcheng JE, Lincoff AM, Sigmon KN, Kitt MM, Califf RM, Topol EF. for the IMPACT II Investigators Platelet glycoproteinHb/nia inhibition with Integrelin during percutaneous coronary intervention: the IMPACT II Trial. Circulation 1995; 92 (suppl) 001-543
• 18 King III SB. Administration of Tirofiban (MK-0383) will reduce the incidence of adverse cardiac outcome following PTCA/ DCA (RESTORE). J Am Coll Cardiol 1996; 27: 001-543 (suppl A)
• 19 Schrör K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993; 04: 252-261
• 20 CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-1338
• 21 De ClerckF, Beertens J, De Chaffoy, de Courcelles D, Freyne E, Janssn PAJ. R68070: Thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule. I. Biochemical profile in vitro. Thromb Haemostas 1989; 61: 35-42
• 22 The RAPT investigators: Randomized Trial of Ridogrel, a Combined Thromboxane A2 Synthase Inhibitor and Thromboxane A2/Prostaglandin Endoperoxide Receptor Antagonist, Versus Aspirin as Adjunct to Thrombolysis in Patients With Acute Myocardial Infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994; 89: 588-595